P10L2

General

Cell Line

hPSCreg name RCMGi011-B
Cite as:
RCMGi011-B (RRID:CVCL_C9HA)
Alternative name(s)
P10L2
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
LUMCi030-B
(LUMC0110iALK10)
Donor diseases:
Hereditary Hemorrhagic Telangiectasia
RCMGi004-A
(P6L2)
Donor diseases:
Cystic Fibrosis
BBANTWi006-A
(iPSC_BrS9_FB_C7)
Donor's gene variants:
SCN5A
Donor diseases:
Brugada syndrome 1
RCMGi001-A
(P1L5)
Donor diseases:
Cystic Fibrosis
RCMGi005-B
(P5L5)
Donor diseases:
Cystic Fibrosis
RCMGi013-A
(P2L2)
Donor's gene variants:
CFTR
Donor diseases:
Cystic Fibrosis
RCMGi005-A
(P5L1)
Donor diseases:
Cystic Fibrosis
LUMCi030-A
(LUMC0110iALK04)
Donor diseases:
Hereditary Hemorrhagic Telangiectasia
RCMGi004-B
(P6L8)
Donor diseases:
Cystic Fibrosis
LUMCi056-A
(CRB1 patient 128 compound heterozygous c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr), LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
MHRCCGi001-A
(P1SH)
Donor diseases:
Schizophrenia
CMGANTi008-A
(iPSC_MFS_FBN1_Fi930129_C8)
Donor diseases:
Marfan Syndrome
LUMCi027-A
(LUMC0153iPKP03)
Donor's gene variants:
PKP2
Donor diseases:
arrhythmogenic right ventricular dysplasia 9
RCMGi002-A
(P7L2)
Donor diseases:
Cystic Fibrosis
BBANTWi007-A
(iPSC_BrS10_FB_C3)
Donor's gene variants:
SCN5A
Donor diseases:
Brugada syndrome 1
RCMGi008-A
(P9L1)
Donor diseases:
Cystic Fibrosis
RCMGi007-A
(P8L2)
Donor diseases:
Cystic Fibrosis
Last update 7th March 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Research Centre for Medical Genetics (RCMG)
Owner Research Centre for Medical Genetics (RCMG)
Distributors
Derivation country Russia

External Databases

BioSamples SAMEA112751261
Cellosaurus CVCL_C9HA
Wikidata Q123033342

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Synonyms
  • Mucopolysaccharidosis Type IVB
  • MPS IV B
Synonyms
  • DFNB12
  • autosomal recessive deafness 12

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
Yes

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA112696501

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent development of commercial products? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? The study was aproved by the local ethics committee of the Federal State Bugetaru Institution
Approval number 2015-05-03
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Collected in 2021

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes

Vector free reprogramming

Other

Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
Unknown

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
CO2 Concentration 5 %
Medium TeSR™ E8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
FOXA2
Yes
Protocol or reference
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Brachyury/TBXT
Unknown
Protocol or reference
Ectoderm
Ont Id: UBERON_0000924
Protocol or reference

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 12
Karyotyping method: G-Banding

Other Genotyping (Cell Line)